SHP615

DRUG2 trials

Sponsors

Shire

Conditions

Nervous System Diseases

Phase 3

Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan

CompletedNCT03336645

ShireNervous System Diseases

Start: 2017-10-23End: 2019-08-19Updated: 2020-07-31

Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

CompletedNCT03336450

ShireNervous System Diseases

Start: 2018-04-23End: 2020-10-13Updated: 2021-09-14

Related Papers

Buccal midazolam for treatment of pediatric status epilepticus in community settings in Japan: A phase 3 open-label extension study

Epilepsy & Seizure2023-01-011 citations